Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy

被引:18
|
作者
Abuqbeitah, Mohammad [1 ]
Demir, Mustafa [1 ]
Uslu-Besli, Lebriz [1 ]
Yeyin, Nami [1 ]
Sonmezoglu, Kerim [1 ]
机构
[1] Istanbul Univ, Cerrahpasa Fac Med, Dept Nucl Med, Istanbul, Turkey
关键词
Lu-177-DOTATATE; Lu-177-PSMA; Radiation exposure; Dose rate; Blood clearance; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS; RECEPTOR;
D O I
10.1007/s00411-017-0721-6
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The main target of this work is to examine blood clearance and external exposure for Lu-177-DOTATATE compared with new emerging Lu-177-PSMA therapy. Blood clearance and radiation exposure of 31 patients treated with 5.5 +/- 1.1 GBq Lu-177-DOTATATE were compared to those of 23 patients treated with 7.4 GBq Lu-177-PSMA. Dose rates were measured at several distances and time points up to 120 h after treatment. Blood samples were collected conjunctively after infusion. Caregiver's cumulative dose was measured by means of an OSL (optically stimulated luminescence) dosimeter for 4-5 days and medical staff's dose was also estimated using electronic personal dosimeters. Finger dose was determined via ring TLD (Thermoluminescence Dosimeter) for radiopharmacists and nurses. Dose rates due to Lu-177-DOTATATE at a distance of 1 m, 4 h and 6 h after infusion, were 3.0 +/- 2.8 and 2 +/- 1.9 A mu Sv/(h GBq), respectively, while those due to Lu-177-PSMA were 3.1 +/- 0.8 and 2.2 +/- 0.9 A mu Sv/(h GBq). Total effective dose of 17 caregivers was 100-200 A mu Sv for Lu-177-DOTATATE therapy. Mean effective doses to nurses and radiopharmacists were 5 and 4 A mu Sv per patient, respectively, while those for physicists and physicians were 2 A mu Sv per patient. For Lu-177-DOTATATE, effective half-life in blood and early elimination phase were 0.31 +/- 0.13 and 4.5 +/- 1 h, while they were found as 0.4 +/- 0.1 and 5 +/- 1 h, respectively, for Lu-177-PSMA. The first micturition time following Lu-177-DOTATATE infusion was noted after 36 +/- 14 min, while the second and third voiding times were after 74 +/- 9 and 128 +/- 41 min, respectively. It is concluded that blood clearance and radiation exposure for Lu-177-DOTATATE are very similar to those for Lu-177-PSMA, and both treatment modalities are reasonably reliable for outpatient treatment, since the mean dose rate [2.1 A mu Sv/(h GBq)] decreased below the dose rate that allows release of the patient from the hospital (20 A mu Sv/h) after 6 h at 1 m distance.
引用
收藏
页码:55 / 61
页数:7
相关论文
共 50 条
  • [1] Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy
    Mohammad Abuqbeitah
    Mustafa Demir
    Lebriz Uslu-Beşli
    Nami Yeyin
    Kerim Sönmezoğlu
    Radiation and Environmental Biophysics, 2018, 57 : 55 - 61
  • [2] Incorporation Of 177Lu During Care Of 177Lu-PSMA And 177Lu-DOTATATE Therapy Patients
    Happel, C.
    Kranert, W. T.
    Bockisch, B.
    Kratzel, U.
    Baumgarten, J.
    Ngoc, C. Nguyen
    Garayev, E.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S842 - S843
  • [3] Administration of 177Lu-PSMA-617 as Compared to 177Lu-Dotatate
    Patel, P.
    McCall, K.
    MEDICAL PHYSICS, 2022, 49 (06) : E811 - E812
  • [4] Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy
    Mair, Christian
    Warwitz, Boris
    Fink, Katharina
    Scarpa, Lorenza
    Nilica, Bernhard
    Maffey-Steffan, Johanna
    Buxbaum, Sabine
    Virgolini, Irene J.
    ANNALS OF NUCLEAR MEDICINE, 2018, 32 (07) : 499 - 502
  • [5] Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy
    Christian Mair
    Boris Warwitz
    Katharina Fink
    Lorenza Scarpa
    Bernhard Nilica
    Johanna Maffey-Steffan
    Sabine Buxbaum
    Irene J. Virgolini
    Annals of Nuclear Medicine, 2018, 32 : 499 - 502
  • [6] Patient-specific pharmacokinetics and dosimetry over multiple therapy cycles during 177Lu-based radionuclide therapy: a study for 177Lu-DOTATATE and 177Lu-PSMA
    Gosewisch, A.
    Ermoschkin, L.
    Ilhan, H.
    Todica, A.
    Vamacka, L.
    Bartenstein, P.
    Boening, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S270 - S271
  • [7] Prostate Cancer With Neuroendocrine Differentiation Recurring After Treatment With 177Lu-PSMA A Chance for 177Lu-DOTATATE Therapy?
    Nesari Javan, Farnaz
    Aryana, Kamran
    Askari, Emran
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (09) : E480 - E482
  • [8] 177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation
    Assadi, Majid
    Pirayesh, Elahe
    Rekabpour, Seyed Javad
    Zohrabi, Farshad
    Jafari, Esmail
    Nabipour, Iraj
    Esmaili, Abdolhamid
    Amini, Abdullatif
    Ahmadzadehfar, Hojjat
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (12) : 978 - 980
  • [9] Receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumours
    Bodei, L.
    Cremonesi, M.
    Grana, C.
    Bartolomei, M.
    Baio, S.
    Bufi, G.
    Fiorenza, M.
    Obenaus, E.
    Paganelli, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S214 - S214
  • [10] Understanding The Radiobiology Of Targeted Radionuclide Therapy With 177lu-dotatate
    Delbart, W.
    Wimana, Z.
    Vercruyssen, M.
    Meuleman, N.
    Ghanem, G.
    Flamen, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S13 - S14